Companion Animal Ear Infection Treatment Market

Market Study on Companion Animal Ear Infection Treatment: Expenditure on animal health swells worldwide, taking the market ahead

Companion Animal Ear Infection Treatment Market by Product Type (Anti-bacterial, Anti-fungal) | Disease Type (Otitis Externa, Otitis Media, Otitis Interna) | Mode of Administration (Topical, Oral, Otic ) - Almost 44% of Total Revenue Generated by Anti-bacterial Product Segment

Industry: Healthcare

Published Date: January-2023

Format: PPT*, PDF, EXCEL

Delivery Timelines: Contact Sales

Number of Pages: 250

Report Price

$ 4900*

Buy Now
Request Report Sample

Report ID: PMRREP33266

Market Snapshot

Newly-released Companion Animal Ear Infection Treatment Market analysis report by Persistence Market Research reveals that global sales of the Companion Animal Ear Infection Treatment Market in 2022 were held at US$ 500.8 Million. With a CAGR of 9.7% from 2023 to 2033, the market is projected to reach a valuation of US$ 1.4 Billion by 2033. Otis Externa Disease Type is expected to be the highest revenue-generating segment, accounting for a CAGR of 10.2% from 2023 to 2033.

Attribute

Details

Global Companion Animal Ear Infection Treatment Market (2023)

US$ 545.4 Million

Global Companion Animal Ear Infection Treatment Market (2033)

US$ 1.4 Billion

Global Companion Animal Ear Infection Treatment Market CAGR (2023 to 2033)

9.7%

U.S. Companion Animal Ear Infection Treatment Market CAGR (2023 to 2033)

9.6%

Key Companies Profiled

  • Zoetis
  • Elanco
  • Dechra Pharmaceuticals
  • Merck & Co., Inc.
  • Vetoquinol
  • Penn Veterinary Supply, Inc.
  • Virbac S.A.
  • Ceva Santé Animale
  • Vedco, Inc.

Revenue of Companion Animal Ear Infection Treatment Market from 2018 to 2022 Compared to Demand Outlook for 2023 to 2033

As per Companion Animal Ear Infection Treatment Market research by Persistence Market Research - a market research and competitive intelligence provider, historically, from 2018 to 2022, the market value of the Companion Animal Ear Infection Treatment Market increased at around 8.2% CAGR.

An ear infection is the second most prevalent ailment in dogs. There are three varieties of otitis externa, otitis media, and otitis interna, depending on which section of the ear is affected. Otitis externa and otitis media affect dogs and cats of all breeds and ages; however, dogs with long ears, such as retrievers and spaniels, and dogs with bushy external canals, such as poodles and terriers, are more susceptible.

The rising prevalence of otitis externa in pets is one of the primary factors driving the market forward. Additionally, rising pet and animal healthcare services are likely to propel the market forward. However, medication side effects and a lack of care may limit the market growth, while aggressive pets and a lack of professionalism would provide a challenge to market expansion. Furthermore, increased public awareness of animal health and hygiene will expand the market for companion animal ear infection treatment.

Which factors are driving the growth of the Companion Animal Ear Infection Treatment Market?

Several factors are predicted to fuel the worldwide market's overall growth. The rising occurrence of otitis externa in dogs is one of the primary growth drivers. The disease has largely affected canine pets, which has fuelled market expansion.

Due to the rigorous lockdown imposed during COVID-19, veterinary clinic operations were constrained, resulting in a decrease in vet visits. This has had a significant impact on the development of the global market. The growing pet population has aided the growth of the global market.

The 'humanization' of pets has resulted from changes in consumer behavior and an increase in pet ownership. Pets have earned status as members of the owner's family in recent years. As a result, pet owners are more likely to spend more on pet supplies, higher-quality food, and costly medical treatment. Furthermore, with the rise in people's disposable income and elevation in their lifestyles, they have been spending more on their pets, which is likely to boost the market during the projection period.

Which Region is projected to Offer the Largest Opportunity for Companion Animal Ear Infection Treatment Market?

Due to rising pet ownership and spending on companion animals, increased research and development activities in animal health, and swelled government expenditure on animal welfare, the market in the Asia Pacific is booming.

According to the Animal Health Alliance (Australia) Ltd., over half of Australia's population, or 48%, wants to obtain a pet or adopt another pet. In 2013, over 1.1 million families (14.9%) in the country planned to get a companion animal. During the projected period, the increased adoption rate of companion animals is expected to boost the market. Due to high disposable income and the rising pharmaceutical and biotechnology industry, the Middle East and Africa, as well as Latin America, are likely to be promising markets.

Country-wise Analysis

U.S. Companion Animal Ear Infection Treatment Market Analysis

The U.S. is projected to account for a significant share of the global market. One of the key factors aiding the development of the market in the country is the existence of well-known animal health enterprises. Furthermore, the region's implementation of veterinary health information systems has improved real-time diagnostics.

Such developments are intended to speed up research and development as well as facilitate the development of new products. Furthermore, in the approaching years, the expanding number of veterinary doctors and clinics in the country is predicted to aid the overall development of the regional industry.

U.K. Companion Animal Ear Infection Treatment Market Analysis

The market in the U.K. is expected to reach a valuation of US$ 47.9 Million by 2033. Growing with a CAGR of 11.4% in the forecast period, the market in the country is projected to garner an absolute dollar opportunity of US$ 31.5 Million.

Japan Companion Animal Ear Infection Treatment Market Analysis

In Japan, the market is expected to grow at a CAGR of 10.8% from 2023 to 2033, reaching US$ 51.3 Million by 2033. The market in the country is expected to gross an absolute dollar opportunity of US$ 32.9 Million during the forecast period.

Category-wise Insights

What are the insights about the Product Type segment?

In 2020, the Anti-bacterial product segment accounted for almost 44% of total revenue. Due to an increase in the number of occurrences of ear infections in dogs, this category will continue to lead during the projection period. Otitis externa is the most common ear illness, with a bacterial infection as the primary cause. A total of 91 out of 122 dogs tested positive for bacterial species, according to a study published in the Asian Pacific Journal of Tropical Biomedicine in 2019.

Aminoglycosides and fluoroquinolones are two prominent anti-bacterial for pets, of which aminoglycosides are the most extensively used antibiotics in companion animals. With the introduction of new brands, industry players are constantly attempting to diversify their product lines. For example, Virbac released an Easoticotic suspension for canine otitis externa in April 2020.

The Otitis Externa Disease Type segment Garnered Significant Revenue in the Companion Animal Ear Infection Treatment Market. Check how?

In 2020, market revenue through otitis externa led to a significant revenue share in the market. Infections in cats' ears are often undetectable due to their quadruped ear canals, causing them to progress if left untreated. Swelling, itching, redness of the skin, head shaking, increased discharge, and scaly skin is some of the symptoms.

Allergy was found to be the most common cause of otitis externa in most investigations. Furthermore, according to the American Veterinary Medical Association (AVMA), up to 16.5% of dogs get OE and its complications at least once in their lives, which can lead to more serious ear infections.

In 2020, the otitis media disease type category also held a significant share. Otitis media is a condition that affects the middle region of the ear canal and occurs in up to 50% of chronic OE patients. Staphylococcus spp. is the most prevalent organism that causes otitis.

Pseudomonas, Proteus, Enterococcus, Streptococcus, and Corynebacterium are among the other microorganisms. Although the ailment is uncommon in horses, if it is not addressed, it can become potentially deadly or a chronic problem.

What are the insights in the Mode of Administration segment in the Companion Animal Ear Infection Treatment Market?

The topical mode of administration segment accounted for a sizable proportion of the market. Ointments, creams, drops, lotions, and other topical products are the common modes of administration. Infectious or inflammatory ear disorders are frequently treated with topical ear medicines. Furthermore, firms are introducing new products in the market. In India, for example, Virbac launched Cortavance, a topical corticosteroid spray, in four metro cities in June 2019. As a result, the category is likely to continue to dominate the market during the forecast period.

Over the projected period, the otic category is expected to grow at the fastest rate. Virbacacts' EASOTIC Otic Suspension is a fast-acting and simple-to-use therapy. The Zoetis SYNOTIC Otic Solution is designed to relieve the inflammation and pruritus associated with acute and chronic otitis in dogs. It is designed to treat bacterial, inflammatory, and fungal infections linked to otitis externa, which is driving the demand.

Why does Treatment for Dogs Represent a Significant Revenue in Companion Animal Ear Infection Treatment Market?

With a market share of approximately 45% in 2022, Companion Animal Ear Infection Treatment for dogs accounts for a significant market share. Ear infections in dogs are the second-most common medical reason for veterinary consultations.

Increased dog ownership in both developed and emerging countries is also contributing to the segment's rise. According to the American Pet Products Association's national pet owners survey for 2019-2020, dog ownership climbed by 10% in 2020 compared to the previous year.

Furthermore, according to the American Pet Products Association, the United States will spend a substantial amount on dog healthcare in 2023, out of all companion animals. This is projected to help the segment flourish as well. The market revenue through cats, on the other hand, is predicted to grow at the fastest pace, with a CAGR of more than 6% over the forecast period. The rise of this market is being driven by increased concerns about the health and hygiene of cats.

Competitive Analysis

With a huge number of small-scale industrial participants, the market is significantly competitive. Key players in the market include Zoetis, Elanco, Dechra Pharmaceuticals, Merck & Co., Inc., Vetoquinol, Penn Veterinary Supply, Inc., Virbac S.A., Ceva Santé Animale, and Vedco, Inc.

Some of the recent developments of key Companion Animal Ear Infection Treatment providers are as follows:

  • In August 2020, Elanco acquired Bayer Animal Health to expand its animal health footprint globally.
  • In August 2020, Elanco granted Dechra Pharmaceuticals the worldwide rights to Osurnia, treatment of otitis externa in dogs associated with susceptible strains of bacteria.
  • In April 2020, Virbac launched Easotic, a prescription drug for the topical treatment of canine otitis externa.
  • In December 2019, Vetoquinol and Klox Technologies signed a global licensing arrangement, which excludes China. Under the agreement, Vetoquinol will develop and commercialize fluorescent light energy (FLE) products of Klox in animal health.

Similarly, recent developments related to companies offering Companion Animal Ear Infection Treatment have been tracked by the team at Persistence Market Research, which is available in the full report.

Market Segments Covered in Companion Animal Ear Infection Treatment Market Analysis

By Product Type

  • Anti-bacterial
    • Aminoglycosides
    • Fluoroquinolones
    • Other Anti-bacterials
  • Anti-fungal
    • Corticosteroids
    • Other Product Types

By Disease Type

  • Otitis Externa
  • Otitis Media
  • Otitis Interna

By Mode of Administration

  • Topical
  • Oral
  • Otic

By Animal Type

  • Dogs
  • Cats
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

To know more about delivery timeline for this report Contact Sales

Companies Covered in This Report

  • Zoetis
  • Elanco
  • Dechra Pharmaceuticals
  • Merck & Co., Inc.
  • Vetoquinol
  • Penn Veterinary Supply, Inc.
  • Virbac S.A.
  • Ceva Santé Animale
  • Vedco, Inc.

Frequently Asked Questions

The global Companion Animal Ear Infection Treatment Market is worth more than US$ 500 Million at present.

The value of the Companion Animal Ear Infection Treatment market is projected to increase at a CAGR of around 9.7% from 2023 to 2033.

The value of the Companion Animal Ear Infection Treatment market increased at a CAGR of around 8.2% during 2018 – 2022.

The Chinese market for Companion Animal Ear Infection Treatment market is projected to expand at a CAGR of around 11.6% during 2023 – 2033.

While the market in South Korea is expected to grow at nearly 9.4%, the market in Japan is projected to register a CAGR of nearly 10.8% during 2023 - 2033.

Thank you for taking time to visit our website, click like if you found the information on this page useful?

This site uses cookies, including third-party cookies, that help us to provide and improve our services.
Google translate